Objectives -To evaluate in naive patients with chronic hepatitis C 1 -the efficacy and safety of one month interferon alpha (IFN-α) induction regimen; 2-the potential virological benefit of a secondary adjunction of ribavirin among HCV-RNA negative patients after 20 weeks of IFN therapy,with or without an initial 4-week IFN induction. Material and methods -151 naive HCV-RNA positive patients presenting with biopsy-proven chronic hepatitis C and elevated ALT were randomised in a 2∶1 ratio in two arms: IFN-α3 MU thrice a week (tiw) for 24 weeks (non-induced patients); IFN-α6 MU daily for two weeks, then 3 MU daily for two weeks then 3 MU tiw for 20 weeks (induced patients). At week 24, HCV-RNA negative patients were randomised to receive in addition or not ribavirin 1-1.2 g daily for 24 additional weeks. Induction efficacy was assessed on the early viral response (EVR) defined as undetectable HCV RNA at week 4 then week 20. Ribavirin efficacy was assessed on the proportion of maintained complete response until the end of follow-up, 24 weeks after discontinuation of treatment. Data were analysed on an intent-to-treat basis. Results -Efficacy of IFN-αinduction: 104 patients were randomised to the non-induction group, 47 to the induction group. Gender, age, genotype distribution and HCV viral load at baseline did not differ significantly between the two groups. There was one treatment discontinuation because of adverse events in induced patients versus four in non-induced patients (P > 0.05). The 4 week EVR was significantly greater in induced patients in patients with HCV genotype 1, 4 or 5 (47%vs 12%, P = 0.0002) only. There was no impact of induction in patients with HCV genotype 2 or 3. Efficacy of ribavirin: at week 24, 28 and 26 HCV-RNA negative patients were randomised to addition of ribavirin or not, respectively. Patients randomised to secondary additive ribavirin were more often HCV-RNA negative at the end of follow-up than patients treated with IFN-αalone: 18/28 (64%) vs 10/26 (39%); P = 0.06. Among patients randomised to bitherapy, the relapse rate was significantly lower in patients with genotype 2 or 3 (0/12 vs 6/13, P = 0.01) and not in those with genotype 1, 4 or 5 (5/11 vs 3/6, P = 0.99). Conclusion-A 4 week IFN-αinduction significantly increases the EVR rate in patients with HCV genotype 1, 4 or 5. Late secondary adjunction of ribavirin to IFN-αfor 6 months in HCV-RNA negative patients after 6 months of IFN-αsignificantly decreases the relapse rate in patients with HCV genotype 2 or 3, but not in patients with genotypes 1, 4 or 5.
展开▼
